Interestingly, dual blockade of TIGIT/CD155 signalling was found to reverse T cell exhaustion and enhance antitumour capability in HNSCC, which shed light in the therapeutic effect of the TIGIT/CD155 pathway in a transgenic mouse model [409]. This evidence concerns the gene PVR and head and neck squamous cell carcinoma.